Evidence map›Paper›PMID 41753796›Full record

ArticleMicroorganisms2026

Recombinant Cytosolic Truncations of Histidine Kinases Retain Function for Targeted In Vitro Investigations.

Jude Kinkead, Alexander D Hondros, Aimee M Figg, Milah M Young, Richele J Thompson, Christian Melander, John Cavanagh

Abstract read
In one paragraph

Article in Microorganisms, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jude KinkeadDepartment of Biochemistry & Molecular Biology, Brody School of Medicine, East Carolina University, 600 Moye Blvd, Greenville, NC 27858, USA.
Alexander D HondrosDepartment of Biochemistry & Molecular Biology, Brody School of Medicine, East Carolina University, 600 Moye Blvd, Greenville, NC 27858, USA.ORCID 0000-0002-2104-9693
Aimee M FiggDepartment of Biochemistry & Molecular Biology, Brody School of Medicine, East Carolina University, 600 Moye Blvd, Greenville, NC 27858, USA.
Milah M YoungDepartment of Chemistry and Biochemistry, University of Notre Dame, 251 Nieuwland Science Hall, Notre Dame, IN 46556, USA.ORCID 0000-0002-6577-3747
Richele J ThompsonDepartment of Biochemistry & Molecular Biology, Brody School of Medicine, East Carolina University, 600 Moye Blvd, Greenville, NC 27858, USA.
Christian MelanderDepartment of Chemistry and Biochemistry, University of Notre Dame, 251 Nieuwland Science Hall, Notre Dame, IN 46556, USA.
John CavanaghDepartment of Biochemistry & Molecular Biology, Brody School of Medicine, East Carolina University, 600 Moye Blvd, Greenville, NC 27858, USA.ORCID 0000-0002-7064-224X

Funding

NIH HHS R01AI136904 to CM/JC.NIH HHS T32GM145773 to CM.
6 · The paper itself

Abstract

Histidine kinases are an integral component of bacterial two-component systems (TCSs), playing a pivotal role in signal transduction pathways, resulting in both resistance and virulence. However, their inherent membrane-bound nature often results in poor solubility, making them difficult to isolate and rendering them incompatible with most in vitro biochemical techniques. Consequently, much of the research on two-component systems has centered on response regulators, limiting both drug discovery efforts and our broader understanding of key signal transduction mechanisms. To address these challenges, we sought to straightforwardly generate cytosolic truncation mutants of histidine kinases that retain their autophosphorylation and phosphotransfer capabilities. Previously, we successfully developed a cytosolic truncation mutant of PmrB (PmrBc) that maintained these critical functions, demonstrating its suitability as a viable surrogate for in vitro investigations, including inhibitor compound screening. Building upon this foundation, we have refined our methods and here demonstrate these improvements by producing functional histidine kinase truncation mutants from the following diverse bacterial species:

Indexed as

functionalhistidine kinasetruncation

Identifiers

PMID41753796
PMCPMC12942934

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.